How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

@article{MichaelWhite2014HowMP,
  title={How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms},
  author={C. Michael White},
  journal={The Journal of Clinical Pharmacology},
  year={2014},
  volume={54}
}
  • C. Michael White
  • Published 1 March 2014
  • Biology
  • The Journal of Clinical Pharmacology
3,4‐Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible adverse effects. These desirable and adverse effects of MDMA are extensions of its fascinating pharmacologic and… 
Key interindividual determinants in MDMA pharmacodynamics
TLDR
The aim of this review is to present the main interindividual determinants in MDMA pharmacodynamics, with special emphasis on sex-gender, race-ethnicity, genetic differences, interactions, and MDMA acute toxicity, as well as possible therapeutic use.
MDMA interactions with pharmaceuticals and drugs of abuse
TLDR
This article provides an overview of the MDMA-DIs with pharmaceuticals and drugs of abuse and points out the relevance of MDMA-DI’s when MDMA is co-administered with Pharmaceuticals that are metabolized by the CYP2D6 due to MDMA inhibitory action.
Stimulant and Designer Drug Use: Primary Care Management.
TLDR
The clinical effects and treatment of persons who use cocaine, methamphetamines, 3,4-methylenedioxymethamphetamine (MDMA), synthetic cannabinoids, and synthetic cathinones are reviewed.
Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational ‘ecstasy’
  • A. Parrott
  • Biology, Psychology
    Behavioural pharmacology
  • 2016
TLDR
It is concluded that the neurohormones oxytocin and cortisol contribute in various ways to the psychobiological effects of recreational ecstasy/MDMA.
Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: Current perspective and future research prospects
TLDR
Current understandings about the psychobiological effects of recreational 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) are debated, and theoretically driven research topics are suggested, to recommend theoretically-driven topics for future research.
Pharmacologic Similarities and Differences Among Hallucinogens
  • K. Waters
  • Biology, Psychology
    Journal of clinical pharmacology
  • 2021
TLDR
The aim of this article is to compare the pharmacologic similarities and differences among substances within the hallucinogen class and their impact on physical and psychiatric effects.
Pharmacologic and clinical assessment of kratom.
  • C. White
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2018
TLDR
There are no published human pharmacologic, pharmacokinetic, or drug interaction studies on kratom or mitragynine, making it virtually impossible to fully understand kratom's therapeutic potential and risks and the populations most likely to benefit or experience harm from its use.
The Psychiatric Utility of MDMA
TLDR
MDMA has garnered attention for its potential use in helping patients suffering from symptoms of PTSD and other psychiatric disorders and has an extensive list of potential benefits and adverse effects.
Use characteristics and harm potential of ecstasy in The Netherlands
Abstract Introduction Ecstasy (MDMA) is a popular recreational drug, but its illegal production and trade in the Netherlands have developed into a serious public order and ecological problem which
Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study
TLDR
Early integration of CytoSorb use may enhance the management of severe MDMA intoxication, though it cannot prove whether clinical improvement was directly related to elimination of MDMA or beneficial effects on rhabdomyolysis, hyperinflammation, or liver failure.
...
1
2
3
4
...

References

SHOWING 1-10 OF 37 REFERENCES
Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
TLDR
Pharmacological effects after the second administration of MDMA were higher than those following the first but lower than expected, and a disproportionate increase in plasma concentrations in MDMA and MDA was observed most likely due to metabolic inhibition.
Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions
TLDR
Besides supportive care, i.e. sedation using benzodiazepines, intravenous hydration, aggressive cooling and correction of electrolytes, it is worthwhile to investigate the usefulness of carvedilol, ketanserin and haloperidol in the treatment of MDMA-intoxicated patients.
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart
TLDR
MDMA pharmacokinetics and metabolic disposition following two doses separated by 2 h show that the contribution of the first dose to the MDMA-induced mechanism-based metabolic inhibition was already apparent and the concentrations of MDMA after the second dose were slightly higher than expected.
Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management.
TLDR
An overview of MDMA pharmacology and acute toxicity will be given followed by a plan for clinical management of patients with acute MDMA toxicity.
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
TLDR
The main aim of this review was to contribute to the understanding of the cellular and molecular mechanisms involved in MDMA neurotoxicity, which can help in the development of therapeutic approaches to prevent or treat the long-term neuropsychiatric complications of MDMA abuse in humans.
Cortisol and 3,4-Methylenedioxymethamphetamine: Neurohormonal Aspects of Bioenergetic Stress in Ecstasy Users
  • A. Parrott
  • Biology, Medicine
    Neuropsychobiology
  • 2009
TLDR
The energizing hormone cortisol is involved in the psychobiology of MDMA, probably via its effects on energy metabolism, and may contribute to the variance in functional and structural consequences of repeated ecstasy usage.
Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
TLDR
The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA and suggest duloxetine may be useful in the treatment of psychostimulant dependence.
Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration
TLDR
MDMA induces oxytocin release in humans, which may be involved in the characteristic prosocial effects of ecstasy, in a double blind, randomized, crossover, and placebo-controlled study in 15 healthy volunteers.
Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption
In this study we investigate the association of cytochrome P450 enzyme CYP2D6, catechol-O-methyl transferase (COMT, Val158Met) and serotonin transporter promoter (5-HTTLPR) genotypes on change in
Interaction of 3,4‐Methylenedioxymethamphetamine and Methamphetamine During Metabolism by In Vitro Human Metabolic Enzymes and in Rats *
TLDR
The results in this study imply that multiple components in ATS tablets can interact to mutually inhibit their metabolism and potentially enhance the toxicity of each component.
...
1
2
3
4
...